MedTrace Logo

Impact of HIV on Measles and Measles Immunisation

NCT00247091 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2005-11-01

No results posted yet for this study

Summary

We conducted a longitudinal study to assess the immunogenicity of standard-titer measles vaccine in HIV-infected and uninfected Zambian children. The study hypothesis was that HIV-infected children would have higher rates of primary and secondary measles vaccine failure compared to uninfected children, contributing to decreased levels of population immunity to measles and facilitating measles virus transmission in regions of high HIV prevalence.

Conditions

Interventions

BIOLOGICAL

standard-titer measles vaccine

Sponsors & Collaborators

  • Burroughs Wellcome

    collaborator INDUSTRY

  • London School of Hygiene and Tropical Medicine

    collaborator OTHER

  • University of Zambia

    collaborator OTHER

  • Johns Hopkins Bloomberg School of Public Health

    lead OTHER

Principal Investigators

  • William J. Moss, MD · Johns Hopkins University Bloomberg School of Public Health

  • Felicity Cutts, MD · London School of Hygiene and Tropical Medicine

  • Francis Kasolo, MD, PhD · University of Zambia

Eligibility

Min Age
2 Months
Max Age
15 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-05-31
Completion
2004-09-30

Countries

  • Zambia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00247091 on ClinicalTrials.gov